The Quantellect read.As of Nov 19, 2026, 4 active firms cover Eton Pharmaceuticals Inc: 4 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets are tightly clustered, $62.00 to $70.00, so the covering firms are broadly aligned. The average target of $67.50 sits 9% above the current $62.07. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.73 next quarter toward $3.31 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS4 active firms
Buy
Strong Buy00%
Buy4100%
Neutral00%
Sell00%
Strong Sell00%
Based on 4 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$67.50
+8.7% upside
Average target across 4 active firms as of Nov 19, 2026 vs $62.07 current
Highest Target$70.00
Average Target$67.50
Lowest Target$62.00
Detailed analyst forecasts for ETON
Showing 1–4 of 4 named analysts shown · 4 active firms in the rating projection
As of Nov 19, 2026, 4 of 4 active firms rate ETON a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
ETON EPS & revenue forecast
EPS · NEXT QUARTER
$0.73
Range $0.73 – $0.73 · 1 analysts · +421% YoY
Next period, 1 analysts expect Eton Pharmaceuticals Inc to earn $0.73 a share (range $0.73 – $0.73), versus $0.14 a year earlier. Full-year consensus is $1.77, growing to $3.31 the year after.
REVENUE · NEXT QUARTER
$65.0M
Range $63.5M – $66.5M · 1 analysts · +168% YoY
Revenue is expected to reach $65.0M (range $63.5M – $66.5M), +167.9% year-over-year. Full-year consensus is $179.9M, rising to $286.9M next year.
Top analysts covering Eton Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ETON.
#1
Chase Knickerbocker
Craig-Hallum · Rank #17
Buy
$62.00-0.1% to target
Overall win rate
61%
+ Follow
#2
Swayampakula Ramakanth
HC Wainwright & Co. · Rank #321
Buy
$70.00+12.8% to target
Overall win rate
38%
+ Follow
#3
ME
Madison El-Saadi
B. Riley Securities
Buy
$70.00+12.8% to target
Coverage
—
+ Follow
#4
GN
Gary Nachman
Canaccord Genuity
Buy
$68.00+9.6% to target
Coverage
—
+ Follow
#5
ME
Madison Elsaadi
B. Riley Securities
Buy
$40.00-35.6% to target
Coverage
—
+ Follow
ETON stock forecast FAQ
What is ETON's average 12-month price target?+
The 4 active firms with a live target average $67.50 for Eton Pharmaceuticals Inc over the next 12 months, ranging from a $70.00 high to a $62.00 low, as of Nov 19, 2026.
Is ETON stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 4 active firms as of Nov 19, 2026, 4 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for ETON?+
The Street-high target is $70.00 (HC Wainwright & Co.), and the Street-low is $62.00 (Craig-Hallum). The average of all 4 active-firm targets is $67.50.
How many active Wall Street firms cover ETON?+
4 active firms have a recognized rating on Eton Pharmaceuticals Inc as of Nov 19, 2026, and 4 active firms carry a live 12-month price target.
Who is the most accurate analyst covering ETON?+
Among analysts who currently cover ETON, Chase Knickerbocker of Craig-Hallum has the strongest overall Quantellect track record (Rank #17). Their current call is Buy with a $62.00 target.
What is Eton Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $0.73 per share (range $0.73 – $0.73) across 1 analysts. Full-year EPS is projected at $1.77, rising to $3.31 the following year.
How much revenue is Eton Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $65.0M (range $63.5M – $66.5M). Full-year revenue is projected at $179.9M, growing to $286.9M next year.
Have analysts been upgrading or downgrading ETON lately?+
As of Nov 19, 2026, 4 of 4 active firms rate ETON a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ETON calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.